<p>根据最近向证券交易委员会（SEC）提交的 13F 文件，维吉尼亚退休系统（VIRGINIA RETIREMENT SYSTEMS ET Al）在第三季度增加了对 Incyte Corporation（纳斯达克股票代码：INCY - 免费报告）股份的持有，增幅为 4.5%。该公司在本季度购买了额外的 33,000 股后，持有 768,325 股生物制药公司的股票。维吉尼亚退休系统在最近的报告期末持有 Incyte 的 0.39%，价值为 65,162,000 美元。</p>
<ul>
<li>Incyte 能否实现 447% 的每股收益预测和管道热度？</li>
</ul>
<p>其他大型投资者最近也买卖了该公司的股票。Harbor Capital Advisors Inc.在第三季度以 26,000 美元的估值购买了 Incyte 的新头寸。FNY Investment Advisers LLC 在第二季度以约 27,000 美元的价格购买了 Incyte 的新股份。Banque Transatlantique SA 在第一季度以约 26,000 美元的价格获得了 Incyte 的新股份。MUFG Securities EMEA plc 在第二季度以约 32,000 美元的价格购买了 Incyte 的新头寸。最后，CYBER HORNET ETFs LLC 在第二季度以约 33,000 美元的价格获得了 Incyte 的新头寸。目前 96.97% 的股票由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>多家研究公司对 INCY 发表了评论。富国银行（Wells Fargo &amp; Company）在 12 月 8 日的研究报告中将 Incyte 的目标价从 97.00 美元上调至 116.00 美元，并给予该股票 “超配” 评级。Zacks Research 在 11 月 10 日的研究报告中将 Incyte 的股票评级从 “强力买入” 下调至 “持有”。加拿大皇家银行（Royal Bank Of Canada）在 10 月 29 日的报告中将 Incyte 的目标价从 81.00 美元上调至 84.00 美元，并给予该股票 “行业表现” 评级。Piper Sandler 在 11 月 4 日的研究报告中将 Incyte 的目标价从 82.00 美元上调至 102.00 美元，并给予该股票 “超配” 评级。最后，Truist Financial 在 12 月 24 日的研究报告中设定了 Incyte 的目标价为 103.00 美元。八位分析师对该股票给予了买入评级，十一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Incyte 目前的共识评级为 “持有”，平均目标价为 99.79 美元。</p>
<ul>
<li>2024 年盈利增长的五大医疗保健股票</li>
</ul>
<p><strong>获取我们最新的 INCY 股票分析</strong></p>
<h2>Incyte 股票下跌 0.4%</h2>
<p>周三，纳斯达克 INCY 的股票开盘价为 98.92 美元。Incyte Corporation 的 1 年最低价为 53.56 美元，1 年最高价为 109.28 美元。该公司的 50 日移动平均线为 100.08 美元，200 日移动平均线为 86.39 美元。公司的流动比率为 3.20，速动比率为 3.13，债务与股本比率为 0.01。该公司的市值为 194.2 亿美元，市盈率为 16.57，市盈增长比率为 0.68，贝塔值为 0.81。</p>
<ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
<p>Incyte（纳斯达克：INCY - 获取免费报告）在 10 月 28 日（星期二）发布了季度财报。该生物制药公司报告本季度每股收益为 2.26 美元，超出分析师的共识预期 1.65 美元，超出幅度为 0.61 美元。Incyte 的净利润率为 24.69%，股本回报率为 26.56%。该公司在本季度的收入为 13.7 亿美元，而共识预期为 12.6 亿美元。在去年同期，该公司每股收益为 1.07 美元。与去年同期相比，Incyte 本季度的收入增长了 20.0%。股票分析师预计 Incyte Corporation 今年将发布 4.86 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在其他消息中，内部人士 Thomas Tray 在 12 月 19 日（星期五）以平均价格 100.00 美元出售了 2,774 股公司的股票，总价值为 277,400.00 美元。交易后，该内部人士直接持有公司 22,973 股，价值为 2,297,300 美元。这笔交易代表其持股减少了 10.77%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，执行副总裁 Lee Heeson 在 11 月 3 日（星期一）以平均价格 94.02 美元出售了 3,074 股公司的股票，总价值为 289,017.48 美元。交易完成后，该执行副总裁持有公司 29,241 股，价值为 2,749,238.82 美元。这代表其持股减少了 9.51%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士共出售了价值 8,708,893 美元的 88,318 股公司股票。目前 17.80% 的股票由公司内部人士持有。</p>
<h2>关于 Incyte</h2>
<p>（免费报告）</p>
<p>Incyte Corporation 是一家总部位于特拉华州威尔明顿的生物制药公司，专注于肿瘤学和炎症领域新疗法的发现、开发和商业化。自 2002 年成立以来，Incyte 已从一家小型研究机构发展成为一家全球企业，推进一系列内部开发和合作的资产。该公司的研发工作集中在小分子药物和生物制剂上，这些药物和生物制剂调节与癌症、自身免疫疾病和罕见疾病相关的关键信号通路。</p>
<p>该公司的旗舰产品是 Jakafi®（ruxolitinib），这是一种被批准用于治疗骨髓纤维化和真性红细胞增多症的 Janus 激酶（JAK）抑制剂。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票超过 Incyte</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微小的 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
<p><strong>想知道其他对 INCY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Incyte Corporation (NASDAQ:INCY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Incyte 吗？</h2>
<p>在你考虑 Incyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Incyte 并不在名单上。</p>
<p>虽然 Incyte 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

因塞特医疗

<p>维吉尼亚退休系统等在第三季度将其在因塞特医疗（NASDAQ:INCY）的持股增加了 4.5%，目前持有 768,325 股，价值 6516 万美元。其他投资者也购买了股份，机构持有的股票占 96.97%。分析师评级各不相同，普遍评级为 “持有”，平均目标价为 99.79 美元。因塞特医疗的股票开盘价为 98.92 美元，市值为 194.2 亿美元。该公司报告第三季度每股收益为 2.26 美元，超出预期，收入同比增长 20%。还注意到高管的内部交易活动</p>

<p>VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in shares of Incyte Corporation (NASDAQ:INCY - Free Report) by 4.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 768,325 shares of the biopharmaceutical company's stock after buying an additional 33,000 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.39% of Incyte worth $65,162,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会（SEC）提交的 13F 文件，维吉尼亚退休系统（VIRGINIA RETIREMENT SYSTEMS ET Al）在第三季度增加了对 Incyte Corporation（纳斯达克股票代码：INCY - 免费报告）股份的持有，增幅为 4.5%。该公司在本季度购买了额外的 33,000 股后，持有 768,325 股生物制药公司的股票。维吉尼亚退休系统在最近的报告期末持有 Incyte 的 0.39%，价值为 65,162,000 美元。</p>
</div><ul>
<li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>Incyte 能否实现 447% 的每股收益预测和管道热度？</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. bought a new position in shares of Incyte during the third quarter valued at $26,000. FNY Investment Advisers LLC bought a new stake in shares of Incyte in the 2nd quarter worth about $27,000. Banque Transatlantique SA acquired a new stake in shares of Incyte during the 1st quarter worth about $26,000. MUFG Securities EMEA plc bought a new position in Incyte during the 2nd quarter valued at about $32,000. Finally, CYBER HORNET ETFs LLC acquired a new position in Incyte in the second quarter valued at about $33,000. 96.97% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也买卖了该公司的股票。Harbor Capital Advisors Inc.在第三季度以 26,000 美元的估值购买了 Incyte 的新头寸。FNY Investment Advisers LLC 在第二季度以约 27,000 美元的价格购买了 Incyte 的新股份。Banque Transatlantique SA 在第一季度以约 26,000 美元的价格获得了 Incyte 的新股份。MUFG Securities EMEA plc 在第二季度以约 32,000 美元的价格购买了 Incyte 的新头寸。最后，CYBER HORNET ETFs LLC 在第二季度以约 33,000 美元的价格获得了 Incyte 的新头寸。目前 96.97% 的股票由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research firms have commented on INCY. Wells Fargo &amp; Company boosted their price objective on Incyte from $97.00 to $116.00 and gave the stock an &#34;overweight&#34; rating in a research note on Monday, December 8th. Zacks Research downgraded shares of Incyte from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, November 10th. Royal Bank Of Canada increased their price objective on shares of Incyte from $81.00 to $84.00 and gave the stock a &#34;sector perform&#34; rating in a report on Wednesday, October 29th. Piper Sandler boosted their target price on shares of Incyte from $82.00 to $102.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, November 4th. Finally, Truist Financial set a $103.00 price target on shares of Incyte in a research note on Wednesday, December 24th. Eight analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Incyte currently has a consensus rating of &#34;Hold&#34; and an average target price of $99.79.</p>
<div class="lb-trans"><p>多家研究公司对 INCY 发表了评论。富国银行（Wells Fargo &amp; Company）在 12 月 8 日的研究报告中将 Incyte 的目标价从 97.00 美元上调至 116.00 美元，并给予该股票 “超配” 评级。Zacks Research 在 11 月 10 日的研究报告中将 Incyte 的股票评级从 “强力买入” 下调至 “持有”。加拿大皇家银行（Royal Bank Of Canada）在 10 月 29 日的报告中将 Incyte 的目标价从 81.00 美元上调至 84.00 美元，并给予该股票 “行业表现” 评级。Piper Sandler 在 11 月 4 日的研究报告中将 Incyte 的目标价从 82.00 美元上调至 102.00 美元，并给予该股票 “超配” 评级。最后，Truist Financial 在 12 月 24 日的研究报告中设定了 Incyte 的目标价为 103.00 美元。八位分析师对该股票给予了买入评级，十一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Incyte 目前的共识评级为 “持有”，平均目标价为 99.79 美元。</p>
</div><ul>
<li>5 top healthcare stocks for earnings growth in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年盈利增长的五大医疗保健股票</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on INCY</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 INCY 股票分析</strong></p>
</div><h2>Incyte Stock Down 0.4%</h2>
<div class="lb-trans"><h2>Incyte 股票下跌 0.4%</h2>
</div><p>Shares of NASDAQ INCY opened at $98.92 on Wednesday. Incyte Corporation has a 1 year low of $53.56 and a 1 year high of $109.28. The firm's 50-day moving average is $100.08 and its 200-day moving average is $86.39. The company has a current ratio of 3.20, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $19.42 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 0.68 and a beta of 0.81.</p>
<div class="lb-trans"><p>周三，纳斯达克 INCY 的股票开盘价为 98.92 美元。Incyte Corporation 的 1 年最低价为 53.56 美元，1 年最高价为 109.28 美元。该公司的 50 日移动平均线为 100.08 美元，200 日移动平均线为 86.39 美元。公司的流动比率为 3.20，速动比率为 3.13，债务与股本比率为 0.01。该公司的市值为 194.2 亿美元，市盈率为 16.57，市盈增长比率为 0.68，贝塔值为 0.81。</p>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.65 by $0.61. Incyte had a net margin of 24.69% and a return on equity of 26.56%. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the previous year, the firm posted $1.07 earnings per share. Incyte's revenue for the quarter was up 20.0% compared to the same quarter last year. Equities analysts expect that Incyte Corporation will post 4.86 EPS for the current year.</p>
<div class="lb-trans"><p>Incyte（纳斯达克：INCY - 获取免费报告）在 10 月 28 日（星期二）发布了季度财报。该生物制药公司报告本季度每股收益为 2.26 美元，超出分析师的共识预期 1.65 美元，超出幅度为 0.61 美元。Incyte 的净利润率为 24.69%，股本回报率为 26.56%。该公司在本季度的收入为 13.7 亿美元，而共识预期为 12.6 亿美元。在去年同期，该公司每股收益为 1.07 美元。与去年同期相比，Incyte 本季度的收入增长了 20.0%。股票分析师预计 Incyte Corporation 今年将发布 4.86 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, insider Thomas Tray sold 2,774 shares of the firm's stock in a transaction on Friday, December 19th. The stock was sold at an average price of $100.00, for a total value of $277,400.00. Following the transaction, the insider directly owned 22,973 shares in the company, valued at $2,297,300. This trade represents a 10.77% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, EVP Lee Heeson sold 3,074 shares of the company's stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $94.02, for a total value of $289,017.48. Following the completion of the sale, the executive vice president owned 29,241 shares of the company's stock, valued at $2,749,238.82. This represents a 9.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 88,318 shares of company stock worth $8,708,893 over the last 90 days. 17.80% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Thomas Tray 在 12 月 19 日（星期五）以平均价格 100.00 美元出售了 2,774 股公司的股票，总价值为 277,400.00 美元。交易后，该内部人士直接持有公司 22,973 股，价值为 2,297,300 美元。这笔交易代表其持股减少了 10.77%。该交易已在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，执行副总裁 Lee Heeson 在 11 月 3 日（星期一）以平均价格 94.02 美元出售了 3,074 股公司的股票，总价值为 289,017.48 美元。交易完成后，该执行副总裁持有公司 29,241 股，价值为 2,749,238.82 美元。这代表其持股减少了 9.51%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士共出售了价值 8,708,893 美元的 88,318 股公司股票。目前 17.80% 的股票由公司内部人士持有。</p>
</div><h2>About Incyte</h2>
<div class="lb-trans"><h2>关于 Incyte</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.</p>
<div class="lb-trans"><p>Incyte Corporation 是一家总部位于特拉华州威尔明顿的生物制药公司，专注于肿瘤学和炎症领域新疗法的发现、开发和商业化。自 2002 年成立以来，Incyte 已从一家小型研究机构发展成为一家全球企业，推进一系列内部开发和合作的资产。该公司的研发工作集中在小分子药物和生物制剂上，这些药物和生物制剂调节与癌症、自身免疫疾病和罕见疾病相关的关键信号通路。</p>
</div><p>The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.</p>
<div class="lb-trans"><p>该公司的旗舰产品是 Jakafi®（ruxolitinib），这是一种被批准用于治疗骨髓纤维化和真性红细胞增多症的 Janus 激酶（JAK）抑制剂。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Incyte</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Incyte</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微小的 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding INCY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 INCY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Incyte Corporation (NASDAQ:INCY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Incyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Incyte 吗？</h2>
</div><p>Before you consider Incyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Incyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Incyte 并不在名单上。</p>
</div><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Incyte 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

弗吉尼亚退休系统等持有因塞特医疗公司价值 6516 万美元的股份